Biocon Biologics

Biocon Biologics to manufacture and commercialise a broadly neutralising antibody for India and select emerging markets

Abevmy 100 and 400 mg is approved for the treatment of metastatic colorectal carcinoma, metastatic breast cancer, non small-cell…

Biocon Biologics, has a footprint in the majority of the top 20 emerging markets and will be a meaningful contributor to the…

Biocon Biologics announced that Shreehas Tambe has been promoted to the position of Deputy Chief Executive Officer of Biocon…

Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth

The partnership coincides with the start of the centenary celebrations of the discovery of insulin

Kixelle, a fast-acting insulin analog indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1…

Biocon Biologics, a subsidiary of Biocon has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand…

Professor Piot is the Director of the London School of Hygiene & Tropical Medicine and the Handa Professor of Global Health

Biocon Biologics had raised over $255 million from global investors from Jan to Nov 2020